相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
Juan Francisco Grau et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8+ T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma
Jossie Rotman et al.
CLINICAL CANCER RESEARCH (2020)
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha et al.
GENOME MEDICINE (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
M Lee et al.
ANNALS OF ONCOLOGY (2019)
LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
A-L Cheng et al.
ANNALS OF ONCOLOGY (2019)
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
Anjelica Hodgson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stacey Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Opal L. Reddy et al.
DIAGNOSTIC PATHOLOGY (2017)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
Stergios Boussios et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
A. Marijne Heeren et al.
MODERN PATHOLOGY (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
PD-L1 Inhibition With MPDL3280A for Solid Tumors
Edward Cha et al.
SEMINARS IN ONCOLOGY (2015)
Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Yasir Y. Elamin et al.
CANCER MICROENVIRONMENT (2015)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Christina L. Roland et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Oxidative stress regulates expression of VEGFR1 in myeloid cells:: Link to tumor-induced immune suppression in renal cell carcinoma
Sergei Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2008)
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion
PA Saunders et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
DH Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses
F Bennett et al.
JOURNAL OF IMMUNOLOGY (2003)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - A 24-year population-based study
HO Smith et al.
GYNECOLOGIC ONCOLOGY (2000)
Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer
LA Koopman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
